Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Itacitinib in Treating Patients with Low Risk Graft Versus Host Disease


This phase II trial studies how well itacitinib works in treating patients with low risk graft versus host disease. Graft versus host disease is the most common serious complication after bone marrow transplant. It occurs when donor immune cells (the graft) attack normal tissue in the recipient’s body. This inflammatory immune system attack can damage the skin, liver, stomach, and / or intestines. Itacitinib may help reduce the inflammation associated with graft versus host disease by blocking the enzymes associated with activating the inflammatory process.
Kitko, Carrie

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: